Crescent Biopharma Inc (CBIO) USD0.01
Sell:$12.88Buy:$15.50
$0.38
(2.60%)
- This stock can be held in a
Stocks and Shares ISA$0.38
(2.60%)$0.38
(2.60%)Company Information
About this company
Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The Company is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Key people
Key facts
- EPICCBIO
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS38000Q2012
- Market cap$216.38m
- Employees4
- Shares in issue13.89m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.